Core Insights - The J. M. Smucker Company (SJM) is a large-cap stock with a market capitalization of $10.6 billion, specializing in branded food and beverage products [1][2] - SJM has a strong portfolio of iconic brands, including Folgers, Dunkin', Milk-Bone, and Meow Mix, which contribute to its market leadership in coffee and pet foods [2] Financial Performance - SJM's stock has experienced a decline of 17.7% from its 52-week high of $120.76, reached on April 3, 2025 [3] - Over the past six months, SJM shares fell by 8.7%, and over the past 52 weeks, they dipped by 9.1%, underperforming the State Street Consumer Staples Select Sector SPDR ETF (XLP) [5] - In Q3, SJM reported an adjusted EPS of $2.38, surpassing Wall Street expectations of $2.27, with revenue of $2.34 billion, exceeding forecasts of $2.32 billion [7] Market Outlook - Analysts maintain a "Moderate Buy" rating for SJM, with a mean price target of $126.20, indicating a potential upside of 27% from current price levels [8]

Company Overview - Nasdaq, Inc. has a market capitalization of $49.8 billion and provides services to capital markets and other industries both in the United States and internationally, operating through three main segments: Capital Access Platforms, Financial Technology, and Market Services [1] - The company is classified as a "large-cap" stock, as it is valued at $10 billion or more, and operates multiple exchanges while offering trading, clearing, and financial surveillance solutions across various asset classes [2] Stock Performance - Nasdaq shares have declined 16.2% from their 52-week high of $101.79, with a 7.6% drop over the past three months, underperforming the Dow Jones Industrials Average, which fell by 2.7% during the same period [3] - Year-to-date, Nasdaq stock has decreased by 10.7%, lagging behind the Dow Jones Industrials Average's 1.4% dip, but has increased by 19.9% over the past 52 weeks, outperforming the Dow's 14.4% return [3] Financial Results - Nasdaq reported record net revenue of $5.2 billion for 2025, marking a 13% increase, with Solutions revenue reaching $4 billion (up 12%), and Q4 net revenue of $1.4 billion (up 13%) [5] - Financial Technology revenue was reported at $498 million (up 14%), and Index revenue grew by 23% to $232 million [5] Competitive Position - In comparison, rival MSCI Inc. has seen a YTD decline of 4% and a 52-week gain of 1.6%, indicating that Nasdaq has outperformed MSCI stock over the past year [6] - Analysts are optimistic about Nasdaq's prospects, with a consensus "Strong Buy" rating from 18 analysts and a mean price target of $112.06, suggesting a potential premium of 30.6% to current levels [6]

Company Overview - Corteva, Inc. (CTVA) has a market capitalization of $52.7 billion and operates in the agriculture sector, providing services across various global markets including North America, Latin America, Asia Pacific, Europe, the Middle East, and Africa [1] - The company has two main segments: Seed and Crop Protection, focusing on advanced seed genetics, traits, and crop protection products to enhance farm productivity and resilience [1][2] Stock Performance - Corteva's shares have decreased by 3.9% from their 52-week high of $80.90, but have increased by 18.6% over the past three months, outperforming the Nasdaq Composite, which declined by 4% during the same period [3] - Year-to-date, CTVA stock is up 15.1%, while the Nasdaq Composite has dropped by 2.3%. Over the past 52 weeks, the stock has returned 28.1%, lagging behind the Nasdaq's 30% return [6] Financial Results - Following the Q4 2025 results, Corteva's shares rose slightly as the adjusted EPS of $0.22 met Wall Street expectations. The company reported a full-year income of $1.20 billion ($1.75 per share) on sales of $17.40 billion, with operating cash flow increasing by 51% to $3.5 billion and free cash flow rising by 69% to $2.9 billion [7] - Management has provided a 2026 outlook of $4 billion to $4.2 billion in operating EBITDA and $3.45 to $3.70 in operating EPS, despite quarterly revenue of $3.91 billion falling short of consensus estimates [8] Analyst Sentiment - Analysts maintain a moderately optimistic outlook for CTVA stock, with a consensus rating of "Moderate Buy" from 22 analysts. The mean price target is set at $83.35, indicating a potential upside of 7.3% from current levels [9]

Company Overview - Texas Instruments Incorporated (TXN) designs, manufactures, and sells semiconductors, focusing on analog integrated circuits (ICs) and embedded processors, with a market cap of $199.5 billion [1] Market Position - TXN is classified as a large-cap stock, reflecting its substantial size and influence in the semiconductor industry, where it is the global leader in analog chip production [2] - The company offers a diverse product range, including processors, microcontrollers, and calculators, which helps mitigate risk and leverage cross-selling opportunities [2] Stock Performance - TXN's stock has experienced a 7.8% decline from its 52-week high of $231.32, reached on February 11, while gaining 32.3% over the past three months, outperforming the Dow Jones Industrials Average's 5.9% gains [3] - Year-to-date, TXN shares rose 23%, significantly outperforming the Dow Jones' 2.3% gains, but over the past 52 weeks, the stock only climbed 6.3%, underperforming the Dow Jones' 13.2% returns [4] Financial Results - In Q4, TXN reported earnings per share (EPS) of $1.27, which fell short of Wall Street's expectations of $1.30, and revenue of $4.42 billion, missing forecasts of $4.44 billion [5] - For Q1, TXN anticipates revenue between $4.3 billion and $4.7 billion [5] Competitive Landscape - Analog Devices, Inc. (ADI) has outperformed TXN, with a year-to-date increase of 31.3% and a 52-week gain of 50.3% [6] - Wall Street analysts maintain a consensus "Moderate Buy" rating for TXN, with a mean price target of $217.22, indicating a potential upside of 1.8% from current levels [6]

Core Viewpoint - Hasbro, Inc. is a leading global toy and game company with a market cap of $11.4 billion, offering a diverse range of products and expanding its brands through digital gaming and entertainment content [1][2]. Financial Performance - In Q3 2025, Hasbro reported an 8% year-over-year revenue increase and a 13% rise in operating profit to $341 million, driven by a 42% revenue surge in the Wizards of the Coast and Digital Gaming segment [5]. - The revenue from MAGIC: THE GATHERING increased by 55%, with an adjusted EPS of $1.68 and a high operating margin of 44% in the Wizards segment, indicating strong profitability [5]. - Hasbro raised its full-year outlook, projecting high-single-digit revenue growth, adjusted operating margins of 22% - 23%, and adjusted EBITDA of $1.24 billion - $1.26 billion [6]. Stock Performance - Shares of Hasbro have slipped 3.8% from their 52-week high of $85.14 but have gained 9.4% over the past three months, outperforming the Dow Jones Industrials Average's 4.4% rise [3]. - Year-to-date, HAS stock is up 46.5%, significantly exceeding the Dow Jones's 13.2% gain, and has surged nearly 41% over the past 52 weeks compared to the Dow's 13.8% return [4]. - Analysts maintain a consensus "Strong Buy" rating for HAS stock, with a mean price target of $92.50, representing a 13% premium to current levels [7].

Company Overview - The J. M. Smucker Company (SJM) is based in Orrville, Ohio, and specializes in manufacturing and marketing branded food and beverage products, with a market cap of $10.8 billion [1] - SJM's principal products include peanut butter, shortening and oils, fruit spreads, canned milk, baking mixes, ready-to-spread frostings, flour, baking ingredients, juices, and beverages [1] Market Position - SJM is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the packaged foods industry [2] - The company boasts a strong portfolio of iconic brands such as Folgers, Dunkin', Milk-Bone, and Meow Mix, which contribute to its market leadership in coffee and pet foods [2] - The recent acquisition of Hostess Brands enhances SJM's presence in the sweet baked snacks segment, supporting future growth [2] Stock Performance - SJM's stock has experienced a decline of 16.3% from its 52-week high of $121.48, reached on March 10 [3] - Over the past three months, SJM stock has marginally declined, underperforming the Dow Jones Industrials Average, which gained 5.5% during the same period [3] - In the longer term, SJM shares rose 6.2% over six months but fell 10.4% over the past 52 weeks, underperforming the Dow Jones Industrials Average's gains of 14.7% and 10.5% respectively [4] - The stock has been trading below its 200-day moving average for the past year and below its 50-day moving average since mid-September [4] Financial Results - On November 25, SJM reported its Q2 results, with an adjusted EPS of $2.10, which fell short of Wall Street expectations of $2.12 [5] - The company's revenue for the quarter was $2.33 billion, surpassing Wall Street forecasts of $2.32 billion [5] - SJM expects its full-year adjusted EPS to be in the range of $8.75 to $9.25 [5] Analyst Sentiment - Wall Street analysts maintain a reasonably bullish outlook on SJM, with a consensus "Moderate Buy" rating from 18 analysts [6] - The mean price target for SJM is $118.19, indicating a potential upside of 16.2% from current price levels [6]

Core Insights - STERIS plc is a leading provider of infection prevention products and services, with a market capitalization of $25.7 billion, offering a diverse range of medical equipment and consumables [1][2] Company Overview - STERIS is categorized as a large-cap stock, emphasizing its significant size and influence in the medical devices industry, particularly in infection prevention [2] - The company’s diverse portfolio serves as a comprehensive solution for healthcare providers, enhancing revenue and customer retention [2] Stock Performance - STERIS shares have experienced a decline of 4.2% from their 52-week high of $268.60, reached on November 25 [3] - Over the past three months, the stock has gained 3.6%, underperforming the S&P 500 Index, which saw a 5% increase [3] - In the longer term, STERIS shares rose 6% over six months, lagging behind the S&P 500's 13.9% gains, but have outperformed the index with a 19.3% increase over the past 52 weeks compared to the S&P 500's 13% [4] Recent Financial Results - On November 5, STERIS reported Q2 results, with revenue of $1.5 billion, exceeding analyst expectations of $1.4 billion [5] - The adjusted EPS of $2.47 also surpassed analyst estimates by 5.1% [5] - In contrast, Stryker Corporation, a competitor, has seen its stock decline by 8.4% over the past 52 weeks [5] Analyst Sentiment - Wall Street analysts maintain a bullish outlook on STERIS, with a consensus "Moderate Buy" rating from nine analysts [6] - The mean price target for STERIS is $288.86, indicating a potential upside of 12.3% from current price levels [6]

Company Overview - Westinghouse Air Brake Technologies Corporation (WAB) is valued at a market cap of $36.7 billion and provides technology-based locomotives, equipment, systems, and services for the freight rail and passenger transit industries [1] - WAB is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size, influence, and dominance in the railroad industry [2] Financial Performance - WAB reported Q3 results with revenue growth of 8.4% year-over-year, reaching $2.9 billion, which surpassed consensus estimates [5] - The adjusted EPS for WAB increased by 16% from the previous year to $2.32, exceeding analyst expectations of $2.23 [5] - Despite the positive earnings report, WAB's stock price fell by 2.3% following the earnings release [5] Stock Performance - WAB's shares have gained 12.6% over the past three months, outperforming the S&P 500 Index's rise of 5.7% during the same period [3] - Year-to-date, WAB shares are up 13.4%, which is lower than the S&P 500's return of 16.7% [4] - Over the past 52 weeks, WAB has increased by 4.6%, while the S&P 500 has risen by 12.7% [4] Market Position and Analyst Sentiment - WAB has outperformed its rival, Trinity Industries, Inc. (TRN), which has seen a decline of 26.4% over the past 52 weeks [6] - Analysts maintain a moderately optimistic outlook for WAB, with a consensus rating of "Moderate Buy" from 13 analysts [6] - The mean price target for WAB is $229.54, indicating a potential 6.6% premium to its current price levels [6]

Company Overview - Edwards Lifesciences Corporation, based in Irvine, California, has a market cap of $50.3 billion and specializes in products and technologies for treating advanced cardiovascular diseases, being the leading manufacturer of tissue heart valves and repair products [1][2]. Stock Performance - Edwards Lifesciences' stock reached a 52-week high of $87.40 on November 26 and is currently trading 2.4% below that peak. The stock has gained 4.8% over the past three months, outperforming the iShares U.S. Medical Devices ETF, which increased by 2.4% during the same period [3]. - Year-to-date, the stock has risen by 15.2% and 19.5% over the past 52 weeks, compared to the iShares U.S. Medical Devices ETF's gains of 9% in 2025 and 4.1% over the past year [4]. Financial Performance - In Q3, Edwards Lifesciences reported a 14.7% year-over-year increase in sales to $1.6 billion, exceeding expectations by 3.3%. The adjusted EPS of $0.67 surpassed consensus estimates by 13.6%. Despite these positive results, the stock dropped 1.2% in the trading session following the earnings release on October 30, but rebounded in the subsequent sessions [5]. Competitive Position - Edwards Lifesciences has outperformed its peer Stryker Corporation, which saw a 3.4% gain year-to-date and a 5.1% decline over the past 52 weeks. Among 31 analysts covering the stock, the consensus rating is a "Moderate Buy," with a mean price target of $93.68, indicating a 9.9% upside potential from current levels [6].

Company Overview - Aon plc is a professional services firm based in Dublin, Ireland, with a market capitalization of $78.9 billion, providing services in risk management, insurance and reinsurance brokerage, human resource consulting, and outsourcing across over 120 countries [1]. Market Position - Aon is classified as a large-cap stock, with its market cap exceeding $10 billion, indicating its significant size and influence in the insurance industry [2]. Stock Performance - Aon stock reached an all-time high of $412.97 on March 3 and is currently trading 14.3% below that peak. Over the past three months, Aon stock has decreased by 3.4%, underperforming the iShares U.S. Insurance ETF, which saw a 1.8% increase [3]. - Year-to-date, Aon stock prices have declined by 1.5%, and over the past 52 weeks, they have dropped by 10%, while the iShares U.S. Insurance ETF gained 6.5% in 2025 and fell by 2.5% over the past year [4]. Recent Financial Results - Following the release of its Q3 results on October 31, Aon stock prices increased by 3.8%. The company's revenue for the quarter grew by 7.4% year-over-year to approximately $4 billion, exceeding expectations by 1.4%. Adjusted EPS rose by 12.1% year-over-year to $3.05, surpassing consensus estimates by 5.5%. Free cash flows increased by 13.5% year-over-year to $1.1 billion [5]. Competitive Analysis - Aon has outperformed its peer Marsh & McLennan Companies, which experienced a 13.6% decline year-to-date and a 21.4% drop over the past year [6]. - Among 23 analysts covering Aon stock, the consensus rating is a "Moderate Buy," with a mean price target of $400.39, indicating a potential upside of 13.1% from current price levels [6].